Evolution of uterine adenomyosis volume during and after GnRH antagonist (linzagolix) treatment: lessons for further clinical trials
letter
OA: bronze
CC0
⤵ 8 in-corpus citations
AI-generated summary
This study investigated changes in uterine adenomyosis volume during and after treatment with the GnRH antagonist linzagolix to inform future clinical trial design.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (7)
- Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis via openalex
- Partial suppression of estradiol: a new strategy in endometriosis management? via openalex
- Pathogenesis of uterine adenomyosis: invagination or metaplasia? via openalex
- Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis via openalex
- Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial via openalex
- W3203416324 via openalex
- W4295895755 via openalex
Cited by (9)
- The interaction between inflammation and estrogen in adenomyosis : from molecular mechanisms to therapeutic strategies 2026
- Effects of Leuprorelin combined with Mirena on endocrine function, emotion, quality of life, and endometrial receptivity in patients with adenomyosis 2025
- Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2 2025
- Conservative surgical treatment for adenomyosis: New options for looking beyond uterus removal 2024
- The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications 2024
- Exploring the Endocrine Mechanisms in Adenomyosis: From Pathogenesis to Therapies 2024
- Exploring the Endocrine Mechanisms in Adenomyosis: From Pathogenesis to Therapies 2024
- Uterine adenomyosis: Is there an impact on in vitro fertilization outcomes? 2023
- Abnormal Uterine Bleeding in Reproductive Age Women: Role of Imaging in the Diagnosis and Management 2023
Source provenance
- europepmc
- last seen: 2026-08-22T06:09:51.966504+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-08-22T06:08:57.679985+00:00
License: CC0
· commercial use OK